Patents by Inventor Robert C. Bast, Jr.

Robert C. Bast, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR TREATMENT OF OVARIAN AND BREAST CANCER
    Publication number: 20240082232
    Abstract: Provided are methods of treating cancer comprising administering to a patient in need thereof a poly (ADP-ribose) polymerase (PARP) inhibitor and a salt-induced kinase 2 (SIK2) inhibitor. Also provided are methods for increasing the duration of remission for cancer, and for enhancing the sensitivity of PARP inhibitors for cancer.
    Type: Application
    Filed: September 18, 2023
    Publication date: March 14, 2024
    Inventors: Zhen LU, Robert C. BAST, JR.
  • COMPOSITIONS AND METHODS FOR TREATMENT OF OVARIAN AND BREAST CANCER
    Publication number: 20220296583
    Abstract: Provided are methods of treating cancer comprising administering to a patient in need thereof a salt-induced kinase 2 (SIK2) inhibitor and at least a first chemotherapeutic drug. Also provided are methods of increasing or enhancing apoptosis of cancer cells in a patient having cancer, comprising administering to the patient a therapeutically effective amount of a SIK2 inhibitor and at least a first chemotherapeutic drug. Also provided are methods of enhancing sensitivity of ovarian cancer cells to a chemotherapeutic drug or to combinations of chemotherapeutic drugs in a patient having ovarian cancer, comprising contacting the cells with a therapeutically effective amount of a SIK2 inhibitor and at least a first chemotherapeutic drug. A method of increasing or enhancing carboplatin-induced DNA damage in a patient having ovarian cancer, comprising administering to the patient a therapeutically effective amount of a SIK2 inhibitor and at least a first chemotherapeutic drug.
    Type: Application
    Filed: January 25, 2022
    Publication date: September 22, 2022
    Inventors: Zhen LU, Robert C. BAST, Jr.
  • Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer
    Patent number: 8323906
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: December 4, 2012
    Assignees: Millennium Pharmaceuticals, Inc., Board of Regents, The University of Texas System
    Inventors: Ole Petter Veiby, Robert C. Bast, Jr., Gordon B. Mills, Gabriel N. Hortobagyi
  • NOVEL COMPOSITIONS AND METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF HUMAN CANCERS
    Publication number: 20120141604
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.
    Type: Application
    Filed: November 4, 2011
    Publication date: June 7, 2012
    Applicants: Millennium Pharmaceuticals, Inc., Mayo Foundation for Medical Education and Research, Board of Regents, The University of Texas System
    Inventors: Edwin Clark, Tallessyn Grenfell-Lee, Karen Lu, Lynn Hartmann, Jeffrey L. Brown, Robert C. Bast, JR., Gordon B. Mills
  • Compositions and methods for the identification, assessment, prevention and therapy of human cancers
    Patent number: 8080368
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: December 20, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Edwin Clark, Tallessyn Grenfell-Lee, Karen Lu, Lynn Hartmann, Jeffrey L. Brown, Robert C. Bast, Jr., Gordon B. Mills
  • COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF BREAST CANCER
    Publication number: 20110092388
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.
    Type: Application
    Filed: November 23, 2010
    Publication date: April 21, 2011
    Applicants: MILLENNIUM PHARMACEUTICALS, INC., Board of Regents, The University of Texas system
    Inventors: JAMES LILLIE, Manjula Gannavarapu, Karen Glatt, Sebastian Hoersch, Shubhangi Kamatkar, Maureen Mertens Hattersley, John E. Monahan, Vickesh Myer, Youzhen Wang, Yong Yao Xu, Xumei Zhao, Rachel E. Meyers, Robert C. Bast, JR., Gabriel N. Hortobagyi, Lajos Pusztai
  • Compositions and methods for the identification, assessment, prevention and therapy of human cancers
    Patent number: 7871775
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.
    Type: Grant
    Filed: December 17, 2007
    Date of Patent: January 18, 2011
    Assignees: Millennium Pharmaceuticals, Inc, Mayo Foundation for Medical Edication and Research, Board of Regents, The University of Texas System
    Inventors: Edwin Clark, Tallessyn Grenfell-Lee, Karen Lu, Lynn Hartmann, Jeffrey L. Brown, Robert C. Bast, Jr., Gordon B. Mills
  • BIOMARKERS FOR THE DETECTION OF EARLY STAGE OVARIAN CANCER
    Publication number: 20100304993
    Abstract: The present invention provides methods and compositions for detecting early stage ovarian cancer in a patient. Also, methods for evaluating the ovarian cancer state of a patient are described herein. These methods involve the detection, analysis, and classification of biomarkers in biological samples.
    Type: Application
    Filed: April 29, 2010
    Publication date: December 2, 2010
    Applicants: VERMILLLION, INC., Board of Regents, The University of Texas System
    Inventors: Eric T. Fung, Charlotte Clarke, Robert C. Bast, JR., Kevin R. Coombes
  • NUCLEIC ACID MOLECULES AND PROTEINS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF OVARIAN CANCER
    Publication number: 20100291068
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers are provided.
    Type: Application
    Filed: March 8, 2010
    Publication date: November 18, 2010
    Applicants: MILLENNIUM PHARMACEUTICALS, INC., Board of Regents, The University of Texas System
    Inventors: Wilson O. Endege, Donna Ford, Manjula Gannavarapu, Karen Glatt, Sebastian Hoersch, Shubhangi Kamatkar, John E. Monahan, Robert Schlegel, Yong Yao Xu, Xumei Zhao, Robert C. Bast, JR., Gordon B. Mills, Karen Lu
  • COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF BREAST CANCER
    Publication number: 20100105051
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.
    Type: Application
    Filed: September 25, 2009
    Publication date: April 29, 2010
    Applicants: MILLENNIUM PHARMACEUTICALS, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS
    Inventors: JAMES LILLIE, MANJULA GANNAVARAPU, KAREN GLATT, SEBASTIAN HOERSCH, SHUBHANGI KAMATKAR, MAUREEN MERTENS HATTERSLEY, JOHN E. MONAHAN, VICKESH MYER, YOUZHEN WANG, YONG YAO XU, XUMEI ZHAO, RACHEL E. MEYERS, ROBERT C. BAST, JR., GABRIEL N. HORTOBAGYI, LAJOS PUSZTAI
  • Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
    Patent number: 7705120
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: April 27, 2010
    Assignees: Millennium Pharmaceuticals, Inc., Board of Regents, University of Texas System
    Inventors: James Lillie, Manjula Gannavarapu, Karen Glatt, Sebastian Hoersch, Shubhangi Kamatkar, Maureen Mertens, Hattersley, John E. Monahan, Vickesh Myer, Youzhen Wang, Yongyao Xu, Xumei Zhao, Rachel E. Meyers, Robert C. Bast, Jr., Gabriel N. Hortobagyi, Lajos Pusztai
  • COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF BREAST CANCER
    Publication number: 20100075325
    Abstract: The invention relates to nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.
    Type: Application
    Filed: September 11, 2009
    Publication date: March 25, 2010
    Applicants: MILLENNIUM PHARMACEUTICALS, INC., Board of Regents, The University of Texas System
    Inventors: John E. Monahan, Sebastian Hoersch, Dustin L. Anderson, Wilson O. Endege, Donna Ford, Karen Glatt, Bella O. Gorbatcheva, Shubhangi Kamatkar, Yong Yao Xu, Manjula Gannavarapu, Xumei Zhao, Robert Schlegel, Maureen Mertens Hattersley, Robert C. Bast, JR., Gabriel N. Hortobagyi, Lajos Pusztai
  • Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
    Publication number: 20100009358
    Abstract: The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers. A variety of newly identified markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of breast cancer.
    Type: Application
    Filed: December 18, 2008
    Publication date: January 14, 2010
    Applicants: Millennium Pharmaceuticals, Inc., Board of Regents, The University of Texas System
    Inventors: Mark D. Ayers, Jim Stec, Andrew Damokosh, Edwin Clark, Kenneth R. Hess, Gabriel N. Hortobagyi, Lajos Pusztai, W. Fraser Symmans, Robert C. Bast, JR.
  • Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer
    Publication number: 20100003682
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided.
    Type: Application
    Filed: December 17, 2008
    Publication date: January 7, 2010
    Applicants: Millennium Pharmaceuticals, Inc., Board of Regents, The University of Texas System
    Inventors: Ole Petter Veiby, Robert C. Bast, JR., Gordon B. Mills, Gabriel N. Hortobagyi
  • Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
    Patent number: 7601505
    Abstract: The invention relates to nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.
    Type: Grant
    Filed: May 26, 2004
    Date of Patent: October 13, 2009
    Assignees: Millennium Pharmaceuticals, Inc., Board of Regents, The University of Texas Systems
    Inventors: John E. Monahan, Sebastian Hoersch, Dustin L. Anderson, Wilson O. Endege, Donna Ford, Karen Glatt, Bella O. Gorbatcheva, Shubhangi Kamatkar, Yong Yao Xu, Manjula Gannavarapu, Xumei Zhao, Robert Schlegel, Maureen Mertens, Robert C. Bast, Jr., Gabriel N. Hortobagyi, Lajos Pusztai
  • Novel compositions and methods for identification, assessment, prevention, and therapy of ovarian cancer
    Publication number: 20090136961
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether ovarian cancer is sensitive or resistant to a therapeutic agent. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with sensitivity or resistance to a therapeutic agent. Thus, by examining the expression of the individual markers of a marker set, also referred to as the expression profile of the marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of the ovarian cancer.
    Type: Application
    Filed: November 18, 2008
    Publication date: May 28, 2009
    Applicants: Millennium Pharmaceuticals, Inc., Board of Regents, Mayo Foundation for Medical Education and Research
    Inventors: Andrew I. Damokosh, Natalia Lartchouk, James J. Stec, II, Edwin A. Clark, Karen Lu, Lynn Hartmann, Robert C. Bast, JR., Gordon B. Mills
  • Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
    Patent number: 7504222
    Abstract: The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers. A variety of newly identified markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of breast cancer.
    Type: Grant
    Filed: October 31, 2002
    Date of Patent: March 17, 2009
    Assignees: Millennium Pharmaceuticals, Inc., Board of Regents, The University of Texas
    Inventors: Mark D. Ayers, Jim Stec, Andrew Damokosh, Edwin Clark, Kenneth R. Hess, Gabriel N. Hortobagyi, Lajos Pusztai, W. Fraser Symmans, Robert C. Bast, Jr.
  • Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer
    Patent number: 7494775
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided.
    Type: Grant
    Filed: March 11, 2005
    Date of Patent: February 24, 2009
    Assignees: Millennium Pharmaceuticals, Inc., UT Board of Regents
    Inventors: Ole Petter Veiby, Robert C. Bast, Jr., Gordon B. Mills, Gabriel N. Hortobagyi
  • Compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer
    Patent number: 7470509
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether ovarian cancer is sensitive or resistant to a therapeutic agent. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with sensitivity or resistance to a therapeutic agent. Thus, by examining the expression of the individual markers of a marker set, also referred to as the expression profile of the marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of the ovarian cancer.
    Type: Grant
    Filed: February 7, 2003
    Date of Patent: December 30, 2008
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Andrew I. Damokosh, Natalia Iartchouk, James J. Stec, II, Edwin A. Clark, Karen Lu, Lynn Hartmann, Robert C. Bast, Jr., Gordon B. Mills
  • Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
    Publication number: 20080311573
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.
    Type: Application
    Filed: June 25, 2007
    Publication date: December 18, 2008
    Applicants: MILLENNIUM PHARMACEUTICALS, INC., Board of Regents, The University of Texas System
    Inventors: James Lillie, Manjula Gannavarapu, Karen Glatt, Sebastian Hoersch, Shubhangi Kamatkar, Maureen Mertens, John E. Monahan, Vickesh Myer, Youzhen Wang, Yongyao Xu, Xumei Zhao, Rachel E. Meyers, Robert C. Bast, JR., Gabriel N. Hortobagyi, Lajos Pusztai, Funda Meric, Aysegul Sahin, Gordon B. Mills